Equity
-€506,759
Debts exceed assets in financial year 2025.
Benno Therapeutics
Lifetime
1 annual account with figurespeak -€194,008 (2025)
-€194,008
lowest -€790,201 (2025)
-€790,201
peak -€506,759 (2025)
-€506,759
€563,483
Board2 names since 2024
1 directorDonna Investco BV
Documentsfilings and deeds
15-06-202646 days before the deadline
2025abbreviated format
Loss of €790,201First year with figures
Key points
from the 2025 annual accountsDebts
€563,483 993% of the balance sheet
After one year 1%Within one year 99%
Of this, €556,682 falls due within a year.
Position in the sector
-893.4%
Lower solvency than 95% of companies in personal services. Sector median 30.7% · 1,384 companies.
Turnover not published (abbreviated format)
Checked score
54
Fair
Financially stronger than 22% of micro companies in personal services (NACE 96)
Probability in this band: 1.5% to 4.2%
Negative equity caps the score at 59.
Bankruptcy probability within 12 months
1.4% Low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.7% across 7,626 companies (NACE 96, micro).
About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
04-2025: 1.6%
05-2025: 1.7%▲ +0.1 percentage points vs 04-2025
06-2025: 2.0%▲ +0.3 percentage points vs 05-2025
07-2025: 2.1%▲ +0.1 percentage points vs 06-2025
08-2025: 2.4%▲ +0.3 percentage points vs 07-2025
09-2025: 2.4%● unchanged vs 08-2025
10-2025: 2.6%▲ +0.2 percentage points vs 09-2025
11-2025: 2.7%▲ +0.1 percentage points vs 10-2025
12-2025: 2.5%▼ -0.2 percentage points vs 11-2025
01-2026: 2.6%▲ +0.1 percentage points vs 12-2025
02-2026: 2.9%▲ +0.3 percentage points vs 01-2026
03-2026: 2.9%● unchanged vs 02-2026
04-2026: 2.9%● unchanged vs 03-2026highest value
05-2026: 2.9%● unchanged vs 04-2026highest value
06-2026: 2.9%● unchanged vs 05-2026highest value
07-2026: 2.9%● unchanged vs 06-2026highest value
08-2026: 2.9%● unchanged vs 07-2026highest value
09-2026: 2.9%● unchanged vs 08-2026
10-2026: 1.4%▼ -1.5 percentage points vs 09-2026lowest value
11-2026: 1.4%● unchanged vs 10-2026lowest value
Financial strengthWeak
Score breakdown
raises risk
Capped at 59: negative equity
Negative equity -€506,759
Founded in 2024
Loss of €790,201 (financial year 2025)
lowers risk
Liquidity: current ratio 0.10, cash €35,366
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 96, micro). It does better than 11% of them on solvency, 47% on liquidity and 9% on profitability.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 7,639 companies had the same profile as Benno Therapeutics has now. Each dot stands for 20 companies, two years later.
84.7%
were still trading
5.6%
stopped another way
8.8%
went bankrupt
Another 0.8% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of Benno Therapeutics itself is lower: 1.4% within 12 months. It rests on far more data about Benno Therapeutics than the profile alone.
Test of the method
The method was tested on the 497,448 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 7,639 companies, not a prediction for Benno Therapeutics. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
No credit on open account
Liquidity is insufficient, with a current ratio of 0.1, below 1. Short-term debt is 981.4% and cash 62.3% of total assets. Equity is negative.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 15-06-2026, 46 days ahead of the deadline.
NBB · 1 filingDeviation from the deadline
2025
46 days early
← before the deadline
after the deadline →
Searched, nothing found (1)
Board and ownership
DI
Donna Investco BV
Director, BLOMSMA Erwin, since 01-03-2024
- DONNA INVESTCO BV all the sharesdeed of 02-10-2026
Recent changes
Capital contribution of €1,000,000
DONNA INVESTCO BV holds all the shares · General meeting of 16-09-2026 · Gazette deed
Capital contribution of €875,000
Contribution: Donna Investco BV · Appointment: Moore Audit BV (company auditor) · Donna Investco BV holds all the shares · General meeting of 15-06-2026 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:1006661347
Incorporation
Founding capital of €283,441.86, 100 shares · Founder: Donna Investco BV (oprichter comparant) · Appointment: Donna Investco BV (statutory director) · published on 05-03-2024 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Benno Therapeutics Leuven | €56,724 | -€194,008 | -893.4% | - |
| 2B SPORTHORSES Retie | €79,600 | -€21,145 | -26.2% | - |
| Cani Casa Nazareth-De Pinte | €40,909 | -€7,873 | -28.2% | - |
| HORSE SPA Hamont-Achel | €33,509 | €1,058 | 9.5% | - |
| Groomyy Antwerp Antwerp | €60,896 | -€8,838 | -37.5% | - |
| WAO CONCEPT PARTNER Braine-l'Alleud | €23,049 | €869 | -42.5% | - |
| FLAIR ALLURE Florennes | €25,324 | -€2,484 | 99.6% | - |
These companies have the same main activity as Benno Therapeutics: pet care services, excluding veterinary services (NACE 96993). They are comparable in size and age: total assets between €23,000 and €79,600, founded between 2023 and 2025.
Official details
Source: KBO- Status
- Active since 01-03-2024Normal situation
- Activity
- Pet care services, excluding veterinary servicesNACE 96993and 2 others
- Establishment unit
- 2.359.553.7043001 Leuven, since 01-03-2024
- Financial year end
- 31 December
- Peppol
- Reachable since 30-10-2025
Annual accounts 2025
- €56,724
- Filing
- Filed on 15-06-2026, 46 days before the end of the filing period
Insights on Benno Therapeutics
Benno Therapeutics has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€506,759) and a net result of -€790,201.
Its solvency ranks better than 5% of 1,384 sector peers (NACE 96, financial year 2025). The computed 12-month bankruptcy probability is 1.4% (low).
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Benno Therapeutics
- What is the company number of Benno Therapeutics?
- The company number of Benno Therapeutics is 1006.661.347. The VAT number is the same number with BE in front: BE 1006.661.347.
- Where is Benno Therapeutics based?
- The registered office is at Ambachtenlaan 1, 3001 Leuven.Company details
- What does Benno Therapeutics do?
- According to the KBO register, the main activity is pet care services, excluding veterinary services (NACE 96993).
- What is the legal form of Benno Therapeutics?
- Benno Therapeutics is a private limited company (BV).
- When was Benno Therapeutics founded?
- Benno Therapeutics was founded on 01-03-2024.
- Is Benno Therapeutics still active?
- Yes, Benno Therapeutics is an active enterprise in the KBO register.
- What is the turnover of Benno Therapeutics?
- The annual accounts for financial year 2025 state no turnover. The abbreviated format does not require it.Financials
- Is Benno Therapeutics profitable?
- In financial year 2025, Benno Therapeutics made a loss of €790,201.
- Where can I find the annual accounts of Benno Therapeutics?
- Benno Therapeutics filed 1 annual account with the National Bank of Belgium, for financial year 2025.
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.